About OZ-Link Technologies

OZ-Link Technologies has developed a modular platform utilizing self-cleaving chemical linkers for precise, time-controlled release of therapeutics, ranging from minutes to weeks. This technology enhances pharmacokinetics and minimizes off-target effects, making it suitable for a variety of applications, including small molecules, biologics, and vaccines.

<problem> Current therapeutic delivery methods often lack precise control over drug release timing, leading to suboptimal pharmacokinetics and increased off-target effects. This lack of control can reduce drug efficacy and increase the risk of adverse reactions, particularly for sensitive molecules like biologics and vaccines. </problem> <solution> OZ-Link Technologies offers a modular platform based on self-cleaving chemical linkers that enable precise, time-controlled release of therapeutics. These linkers can be customized to release drugs over a range of timescales, from minutes to weeks, allowing for optimized drug delivery profiles. By controlling the timing of drug release, OZ-Link's technology enhances pharmacokinetics, minimizes off-target effects, and improves the overall therapeutic index of various drug modalities, including small molecules, biologics, and vaccines. </solution> <features> - Customizable self-cleaving chemical linkers for controlled drug release - Tunable release kinetics ranging from minutes to weeks - Modular platform adaptable to various therapeutic modalities (small molecules, biologics, vaccines) - Enhanced pharmacokinetics and reduced off-target effects </features> <target_audience> The primary target audience includes pharmaceutical companies and research institutions developing novel therapeutics or seeking to improve the delivery of existing drugs. </target_audience>

What does OZ-Link Technologies do?

Where is OZ-Link Technologies located?

OZ-Link Technologies is based in Atlanta, United States.

When was OZ-Link Technologies founded?

OZ-Link Technologies was founded in 2022.

Who founded OZ-Link Technologies?

OZ-Link Technologies was founded by Steve Seo, Wenting Shi and Jasmine (Jimin) Hwang.

Steve Seo - Co-founder/Chief Operating Officer
Wenting Shi - Co-Founder
Jasmine (Jimin) Hwang - Co-founder/Chief Scientific Officer

Location

Atlanta, United States

Founded

2022

Employees

5 employees

Looking for specific startups?

Try our free semantic startup search

OZ-Link Technologies

Score: 31/100

AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

ozlinktech.com 200+

Founded 2022 – Atlanta, United States

Funding

No funding information available. Click "Fetch funding" to run a targeted funding scan.

Team (5+)

Steve Seo

Co-founder/Chief Operating Officer

Wenting Shi

Co-Founder

Jasmine (Jimin) Hwang

Co-founder/Chief Scientific Officer

Company Description

Problem

Current therapeutic delivery methods often lack precise control over drug release timing, leading to suboptimal pharmacokinetics and increased off-target effects. This lack of control can reduce drug efficacy and increase the risk of adverse reactions, particularly for sensitive molecules like biologics and vaccines.

Solution

OZ-Link Technologies offers a modular platform based on self-cleaving chemical linkers that enable precise, time-controlled release of therapeutics. These linkers can be customized to release drugs over a range of timescales, from minutes to weeks, allowing for optimized drug delivery profiles. By controlling the timing of drug release, OZ-Link's technology enhances pharmacokinetics, minimizes off-target effects, and improves the overall therapeutic index of various drug modalities, including small molecules, biologics, and vaccines.

Features

Customizable self-cleaving chemical linkers for controlled drug release

Tunable release kinetics ranging from minutes to weeks

Modular platform adaptable to various therapeutic modalities (small molecules, biologics, vaccines)

Enhanced pharmacokinetics and reduced off-target effects

Target Audience

The primary target audience includes pharmaceutical companies and research institutions developing novel therapeutics or seeking to improve the delivery of existing drugs.